Zynerba Pharmaceuticals Inc (ZYNE) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access ZYNE Annual Balance Sheets →
Balance sheet data covering Zynerba Pharmaceuticals Inc–Jun 30 2022 offers a view into how Jun 30 2023's financial position has changed alongside business activity.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2023)
(Mar 31 2023) (Dec 31 2022) (Sep 30 2022) (Jun 30 2022)
Assets
Cash & cash equivalent35.97
Cash & Short-term Investments35.00
Other Current Assets1.31
Prepaid Expense And Other Assets Current2.02
Total Current Assets39.29
Equipment/Property/Plant Net0.39
Other Assets, Noncurrent0.79
Tax Incentive Receivable Current1.31
Incentive And Tax Receivables Noncurrent0.57
Total Assets40.48
Liabilities
Accounts Payable, Current AC2.48
Accrued Liabilities, Current AC8.76
Other Liabilities, Current0.00
Total Current Liabilities11.46
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
OperatingLeaseLiabilityNoncurrent-
Operating Lease Liability Current0.22
Total Liabilities11.46
Stockholders' Equity
Common Stock Value0.05
Additional Paid In Capital Common Stock324.37
Retained Earnings / Accumulated Deficit-295.41
Other Equity0.00
Common Stockholder's Equity29.02
Total Stockholder's Equity29.02
Liabilities & Stockholder's Equity40.48
4 historic quarters locked

Sign in to unlock the full Zynerba Pharmaceuticals Inc balance sheet history.

About Zynerba Pharmaceuticals Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001558370-23-014705

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.